Parkinson’s test-and-drug duo wins CPHI award

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

German biotech MODAG won for pairing a CE-marked diagnostic with a drug candidate that targets the same protein.

The jury at CPHI Milan had a pattern to break. For three years running, the API Development and Innovation award had gone to manufacturers with new production processes. On 6 October, it went to a small German company that makes a test and a drug candidate, and wants them used together.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE